Page last updated: 2024-09-05

lapatinib and pazopanib

lapatinib has been researched along with pazopanib in 26 studies

Compound Research Comparison

Studies
(lapatinib)
Trials
(lapatinib)
Recent Studies (post-2010)
(lapatinib)
Studies
(pazopanib)
Trials
(pazopanib)
Recent Studies (post-2010) (pazopanib)
1,9193051,4421,1472371,028

Protein Interaction Comparison

ProteinTaxonomylapatinib (IC50)pazopanib (IC50)
Multidrug resistance-associated protein 4Homo sapiens (human)8.1
Tyrosine-protein kinase ABL1Homo sapiens (human)2.2043
Macrophage colony-stimulating factor 1 receptorHomo sapiens (human)0.21
Cytochrome P450 3A4Homo sapiens (human)0.03
Platelet-derived growth factor receptor betaHomo sapiens (human)0.0837
Cytochrome P450 2D6Homo sapiens (human)0.03
Mast/stem cell growth factor receptor KitHomo sapiens (human)0.0887
Fibroblast growth factor receptor 1Homo sapiens (human)0.1477
Platelet-derived growth factor receptor alphaHomo sapiens (human)0.071
Vascular endothelial growth factor receptor 1 Homo sapiens (human)0.032
Fibroblast growth factor receptor 2Homo sapiens (human)0.14
AcetylcholinesteraseHomo sapiens (human)0.93
Vascular endothelial growth factor receptor 3Homo sapiens (human)0.0467
Vascular endothelial growth factor receptor 2Homo sapiens (human)0.4929
Receptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)0.873
Discoidin domain-containing receptor 2Homo sapiens (human)0.0505
Receptor protein-tyrosine kinase Homo sapiens (human)2.2043

Research

Studies (26)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (7.69)29.6817
2010's22 (84.62)24.3611
2020's2 (7.69)2.80

Authors

AuthorsStudies
Atteridge, CE; Campbell, BT; Chan, KW; Ciceri, P; Davis, MI; Edeen, PT; Faraoni, R; Floyd, M; Gallant, P; Herrgard, S; Hunt, JP; Karaman, MW; Lockhart, DJ; Milanov, ZV; Morrison, MJ; Pallares, G; Patel, HK; Pritchard, S; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Hajduk, PJ; Johnson, EF; Kifle, L; Merta, PJ; Metz, JT; Soni, NB1
Russu, WA; Shallal, HM1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V1
Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Bullock, AN; Canning, P; Choi, S; Cuny, GD; Mohedas, AH; Sanvitale, CE; Wang, Y; Xing, X; Yu, PB1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Jones, LH; Nadanaciva, S; Rana, P; Will, Y1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1
Commo, F; Dessen, P; Kroemer, G; Lacroix, L; Lazar, V; Olaussen, KA; Raza, SQ; Richon, C; Soria, JC; Tailler, M; Vitale, I1
Alber, JA; Ding, J; Mas Lopez, L; Monk, BJ; Oaknin, A; Pandite, LN; Stutts, MW; Tarpin, C; Termrungruanglert, W; Zarba, JJ1
Ghazaly, E; Joel, S; Kitromilidou, C; McGrowder, EH; Perry, J; Powles, T1
Arumugham, T; de Jonge, MJ; Hamberg, P; Hodge, J; Hurwitz, HI; Pandite, LN; Savage, S; Suttle, AB; Verweij, J1
Alvarez, RH; Blackwell, KL; Cristofanilli, M; Gladkov, O; Gomez, HL; Johnston, SR; Manikhas, A; Ranganathan, S; Redhu, S; Rubin, SD; Safina, S; Shao, Z; Trudeau, ME1
Durante, M; Gómez, H; Goodman, V; Johnston, SR; Pandite, L; Richie, M; Slamon, D; Stemmer, SM1
Barriuso, J; Curtis, CM; Dar, MM; de Bono, J; Groves, MD; Ma, B; McLendon, RE; Mikkelsen, T; Nabors, L; Raizer, J; Reardon, DA; Rosenfeld, S; Suttle, AB; Wen, PY1
Hunt, CM; Spraggs, CF; Xu, CF1
Ando, Y; Araki, K; Inada-Inoue, M; Ishida, H; Kawada, K; Mitsuma, A; Mizuno, K; Nagamatsu, K; Nagashima, F; Sasaki, Y; Sawaki, M; Sunakawa, Y; Takekura, A; Yamashita, K; Yokoyama, T1
Bendell, J; Burris, HA; Dowlati, A; Infante, JR; Jones, SF; Kane, MP; Levinson, KT; Stein, MN; Suttle, AB; Tan, AR1
Briley, LP; du Bois, A; Johnson, T; Parham, LR; Russo, M; Song, K; Spraggs, CF; Tada, H; Xu, CF1
Fu, S; George, GC; Henary, H; Hong, DS; Kurzrock, R; Mistry, R; Naing, A; Piha-Paul, S; Wheler, J; Zinner, R1
Burns, K; Chau, N; Kichenadasse, G; Knights, KM; Mackenzie, PI; McKinnon, RA; Miners, JO; Rowland, A; Tucker, GT1
Badolo, L; Jede, C; Koziolek, M; Kubas, H; Lecomte, M; Wagner, C; Weber, C; Weigandt, M; Weitschies, W1
Bharathan, R; Chuai, Y; Dai, G; Li, Y; Otter, SJ; Rizzuto, I; Stewart, A; Wang, A; Zhang, X1
Assis, C; de Souza Bezerra, R; Lacerda Cintra, AJ; Li, C; Martins do Vale, WK; Max Gomes Martins, R; Meira Menezes, T; Neves, JL; Seabra, GM; Silva Dos Santos, RC1

Reviews

3 review(s) available for lapatinib and pazopanib

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors.
    Pharmacogenomics, 2013, Volume: 14, Issue:5

    Topics: Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug-Related Side Effects and Adverse Reactions; Gilbert Disease; Glucuronosyltransferase; Humans; Indazoles; Lapatinib; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Sulfonamides

2013
Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer.
    The Cochrane database of systematic reviews, 2021, 03-04, Volume: 3

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Bevacizumab; Bias; Brachytherapy; Combined Modality Therapy; Confidence Intervals; Female; Gastric Fistula; Gastrointestinal Hemorrhage; Humans; Hypertension; Indazoles; Intestinal Fistula; Intestinal Perforation; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Pyridines; Pyrimidines; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Sulfonamides; Thromboembolism; Uterine Cervical Neoplasms; Vascular Endothelial Growth Factor A; Young Adult

2021

Trials

8 trial(s) available for lapatinib and pazopanib

ArticleYear
Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Aug-01, Volume: 28, Issue:22

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Delivery Systems; Female; Humans; Indazoles; Lapatinib; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Recurrence; Retreatment; Sulfonamides; Uterine Cervical Neoplasms

2010
Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors.
    Investigational new drugs, 2013, Volume: 31, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Indazoles; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Sulfonamides; Young Adult

2013
A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer.
    Breast cancer research and treatment, 2013, Volume: 137, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Disease-Free Survival; Female; Humans; Indazoles; Inflammatory Breast Neoplasms; Lapatinib; Middle Aged; Pyrimidines; Quinazolines; Receptor, ErbB-2; Sulfonamides; Treatment Outcome

2013
A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer.
    Breast cancer research and treatment, 2013, Volume: 137, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Female; Humans; Indazoles; Lapatinib; Middle Aged; Neoplasm Staging; Pyrimidines; Quinazolines; Receptor, ErbB-2; Sulfonamides; Treatment Outcome

2013
A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Feb-15, Volume: 19, Issue:4

    Topics: Adult; Angiogenesis Inhibitors; Anticonvulsants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease-Free Survival; Drug Delivery Systems; ErbB Receptors; Glioma; Humans; Indazoles; Lapatinib; Neoplasm Recurrence, Local; Neoplasm Staging; Pyrimidines; Quinazolines; Recurrence; Sulfonamides

2013
Phase 1 study of pazopanib alone or combined with lapatinib in Japanese patients with solid tumors.
    Cancer chemotherapy and pharmacology, 2014, Volume: 73, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Lapatinib; Male; Middle Aged; Neoplasms; Pyrimidines; Quinazolines; Sulfonamides

2014
Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies.
    British journal of cancer, 2014, May-27, Volume: 110, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Indazoles; Lapatinib; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pyrimidines; Quinazolines; Salivary Gland Neoplasms; Sulfonamides; Treatment Outcome

2014
A phase 1 study of intermittently administered pazopanib in combination with continuous daily dosing of lapatinib in patients with solid tumors.
    Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Female; Gene Amplification; Humans; Indazoles; Lapatinib; Male; Middle Aged; Mutation; Neoplasms; Proto-Oncogene Proteins c-met; Pyrimidines; Quinazolines; Receptor, ErbB-2; Sulfonamides

2015

Other Studies

15 other study(ies) available for lapatinib and pazopanib

ArticleYear
A quantitative analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2008, Volume: 26, Issue:1

    Topics: Binding Sites; Enzyme Activation; Humans; Phosphotransferases; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Proteome; Quantitative Structure-Activity Relationship

2008
Navigating the kinome.
    Nature chemical biology, 2011, Volume: 7, Issue:4

    Topics: Drug Design; Pharmacogenetics; Protein Kinases; Proteome; Systems Biology

2011
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:6

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship

2011
FDA-approved drug labeling for the study of drug-induced liver injury.
    Drug discovery today, 2011, Volume: 16, Issue:15-16

    Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011
Comprehensive analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2011, Oct-30, Volume: 29, Issue:11

    Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity

2011
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
    Journal of medicinal chemistry, 2014, Oct-09, Volume: 57, Issue:19

    Topics: Activin Receptors, Type I; Aminopyridines; Humans; Mutation; Myositis Ossificans; Phenols; Protein Kinase Inhibitors; Structure-Activity Relationship

2014
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
    Bioorganic & medicinal chemistry letters, 2016, 08-15, Volume: 26, Issue:16

    Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone

2016
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017
Synergistic proapoptotic effects of the two tyrosine kinase inhibitors pazopanib and lapatinib on multiple carcinoma cell lines.
    Oncogene, 2009, Dec-03, Volume: 28, Issue:48

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Indazoles; Lapatinib; Male; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Quinazolines; Signal Transduction; Sulfonamides; Xenograft Model Antitumor Assays

2009
A synergistic interaction between lapatinib and chemotherapy agents in a panel of cell lines is due to the inhibition of the efflux pump BCRP.
    Molecular cancer therapeutics, 2010, Volume: 9, Issue:12

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Cycle; Cell Line, Tumor; Chromatography, High Pressure Liquid; Cisplatin; Drug Screening Assays, Antitumor; Drug Synergism; Flow Cytometry; Humans; Indazoles; Intracellular Space; Lapatinib; Neoplasm Proteins; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Sulfonamides

2010
Different effects of the BIM deletion polymorphism on treatment of solid tumors by the tyrosine kinase inhibitors (TKI) pazopanib, sunitinib, and lapatinib.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:7

    Topics: Angiogenesis Inhibitors; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Gene Deletion; Humans; Indazoles; Indoles; Lapatinib; Membrane Proteins; Neoplasms; Polymorphism, Genetic; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Sulfonamides; Sunitinib

2015
Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia.
    Biochemical pharmacology, 2017, 04-01, Volume: 129

    Topics: Bilirubin; Catalysis; Enzyme Inhibitors; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Indazoles; Kinetics; Lapatinib; Microsomes, Liver; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Quinazolines; Sorafenib; Sulfonamides

2017
Improved Prediction of in Vivo Supersaturation and Precipitation of Poorly Soluble Weakly Basic Drugs Using a Biorelevant Bicarbonate Buffer in a Gastrointestinal Transfer Model.
    Molecular pharmaceutics, 2019, 09-03, Volume: 16, Issue:9

    Topics: Administration, Oral; Animals; Bicarbonates; Buffers; Chemical Precipitation; Drug Delivery Systems; Drug Liberation; Female; Gastrointestinal Absorption; Gastrointestinal Tract; Hydrogen-Ion Concentration; Indazoles; Ketoconazole; Lapatinib; Methylcellulose; Models, Biological; Phosphates; Pyrimidines; Rats; Rats, Wistar; Solubility; Sulfonamides

2019
Binding Mechanism between Acetylcholinesterase and Drugs Pazopanib and Lapatinib: Biochemical and Biophysical Studies.
    ACS chemical neuroscience, 2021, 12-15, Volume: 12, Issue:24

    Topics: Acetylcholinesterase; Binding Sites; Indazoles; Lapatinib; Pharmaceutical Preparations; Protein Binding; Pyrimidines; Sulfonamides; Thermodynamics

2021